Literature DB >> 16013192

Suboptimal intensity of risk factor modification in PAD.

Roberta K Oka1, Eva Umoh, Andrzej Szuba, John C Giacomini, John P Cooke.   

Abstract

This study extends earlier trials indicating that atherosclerosis risk factors are underdetected and undertreated in peripheral arterial disease (PAD) patients. Recognition and treatment of hyperlipidemia and hypertension in PAD patients is suboptimal. Diabetes appears to be detected more frequently although glycemic control is still suboptimal. The use of antiplatelet therapy is particularly underutilized. Additionally, despite the demonstrated efficacy of regular exercise in PAD patients, almost half of the study sample was sedentary. Approximately one third of the current study sample was overweight and nearly one third was obese by ATP-III guidelines. Only 31% of subjects were taking dietary measures to improve their cardiovascular health, and even fewer were physically active. To rectify suboptimal management of risk factors, there is a need for increased public awareness of PAD, reimbursement and implementation of screening programs and more aggressive treatment. Future studies are needed to examine innovative interventions for identification and management of cardiovascular risk factors in patients with PAD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16013192     DOI: 10.1191/1358863x05vm611oa

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  9 in total

Review 1.  Biomarkers of peripheral arterial disease.

Authors:  John P Cooke; Andrew M Wilson
Journal:  J Am Coll Cardiol       Date:  2010-05-11       Impact factor: 24.094

2.  Incidence of and factors associated with achieving target lipid levels in patients with peripheral arterial disease.

Authors:  Meggan R Banta; Fangchao Ma; Dawn M Bravata; Robert S Kirsner; Daniel G Federman
Journal:  J Gen Intern Med       Date:  2006-07       Impact factor: 5.128

3.  Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease.

Authors:  Andrew M Wilson; David S Shin; Carlton Weatherby; Randall K Harada; Martin K Ng; Nandini Nair; Jan Kielstein; John P Cooke
Journal:  Vasc Med       Date:  2010-05-19       Impact factor: 3.239

4.  Plasma NAP-2 levels are associated with critical limb ischemia in peripheral arterial disease patients.

Authors:  Xiufang Wang; Juyi Li; Liming Gan; Qun Liu
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-12

Review 5.  Antithrombotic treatment for peripheral arterial disease.

Authors:  Daniel G Hackam; John W Eikelboom
Journal:  Heart       Date:  2006-10-11       Impact factor: 5.994

6.  The combination of 9p21.3 genotype and biomarker profile improves a peripheral artery disease risk prediction model.

Authors:  Kelly P Downing; Kevin T Nead; Yoko Kojima; Themistocles Assimes; Lars Maegdefessel; Thomas Quertermous; John P Cooke; Nicholas J Leeper
Journal:  Vasc Med       Date:  2013-12-09       Impact factor: 3.239

7.  A biomarker panel for peripheral arterial disease.

Authors:  Eric T Fung; Andrew M Wilson; Fujun Zhang; Nathan Harris; Kim A Edwards; Jeffrey W Olin; John P Cooke
Journal:  Vasc Med       Date:  2008-08       Impact factor: 3.239

8.  Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada.

Authors:  Kiran K Kundhal; Siu Lim Chin; Lisa Harrison; Barbara Nowacki; Budhendra Doobay; Jacques Titley; Claudio Ciná; Sonia S Anand
Journal:  Can J Cardiol       Date:  2007-04       Impact factor: 5.223

9.  Surveillance of Peripheral Arterial Disease Cases Using Natural Language Processing of Clinical Notes.

Authors:  Naveed Afzal; Sunghwan Sohn; Christopher G Scott; Hongfang Liu; Iftikhar J Kullo; Adelaide M Arruda-Olson
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2017-07-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.